After two rejections, Fennec Pharmaceuticals finally secured FDA approval for its only asset, Pedmark. Additionally, the company secured non-dilutive capital to help initial commercialization efforts.
Fennec Pharmaceuticals markets Pedmark to reduce cisplatin-induced ototoxicity in pediatric patients but faces challenges in adoption. FENC has missed financial projections, with revenues below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results